NewAmsterdam Pharma Co N.V. (NAMS) stock
NAMSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NAMSW
$19.74+0.35 (+1.81%)
Close on Nov 18, 2026Market cap $2.36BP/E –Yield –
NewAmsterdam Pharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
NewAmsterdam Pharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$143.46M. For fiscal 2025 it was -$147.78M. The highest annual figure on record is $10.67M in fiscal 2022.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$147.78M | – |
| FY2024 | Dec 31, 2024 | -$158.56M | – |
| FY2023 | Dec 31, 2023 | -$141.22M | -1424.1% |
| FY2022 | Dec 31, 2022 | $10.67M | – |
| FY2021 | Dec 31, 2021 | -$29.51M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$39.21M | – |
| Q1 FY2026 | Mar 31, 2026 | -$30.60M | – |
| Q4 FY2025 | Dec 31, 2025 | -$40.88M | – |
| Q3 FY2025 | Sep 30, 2025 | -$32.77M | – |
| Q2 FY2025 | Jun 30, 2025 | -$37.67M | – |
| Q1 FY2025 | Mar 31, 2025 | -$36.47M | – |
| Q4 FY2024 | Dec 31, 2024 | -$37.48M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.50M | – |
| Q2 FY2024 | Jun 30, 2024 | -$53.98M | – |
| Q1 FY2024 | Mar 31, 2024 | -$54.60M | – |
| Q4 FY2023 | Dec 31, 2023 | -$33.07M | – |
| Q3 FY2023 | Sep 30, 2023 | -$46.98M | – |
| Q2 FY2023 | Jun 30, 2023 | -$29.31M | – |
| Q1 FY2023 | Mar 31, 2023 | -$31.86M | – |
See a number that looks wrong?